Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 More on bevacizumab in hereditary hemorrhagic telangiectasia.

× No keyword cloud information.

14 in total

1. [Rendu-Osler-Weber disease : More than just a nosebleed].

Authors: E Lücke; J Schreiber; M Zencker; R Braun-Dullaeus; J Herold
Journal: Internist (Berl) Date: 2016-06 Impact factor: 0.743

Review 2. Cerebrovascular disorders: molecular insights and therapeutic opportunities.

Authors: Erik Storkebaum; Annelies Quaegebeur; Miikka Vikkula; Peter Carmeliet
Journal: Nat Neurosci Date: 2011-10-26 Impact factor: 24.884

3. Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.

Authors: Y H Kim; M-J Kim; S-W Choe; D Sprecher; Y J Lee; S P Oh
Journal: J Thromb Haemost Date: 2017-05-03 Impact factor: 5.824

4. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Authors: C Rohrmeier; H G Sachs; T S Kuehnel
Journal: Eur Arch Otorhinolaryngol Date: 2011-07-31 Impact factor: 2.503

Review 5. Inverted papillomas and benign nonneoplastic lesions of the nasal cavity.

Authors: John W Wood; Roy R Casiano
Journal: Am J Rhinol Allergy Date: 2012 Mar-Apr Impact factor: 2.467

Review 6. Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.

Authors: Wanqiu Chen; Eun-Jung Choi; Cameron M McDougall; Hua Su
Journal: Transl Stroke Res Date: 2014-04-12 Impact factor: 6.829

7. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.

Authors: Narendranath Epperla; William Hocking
Journal: Clin Med Res Date: 2014-03-25

8. A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab.

Authors: Ahmad Amanzada; Gwen-Jana Töppler; Silke Cameron; Harald Schwörer; Giuliano Ramadori
Journal: Case Rep Oncol Date: 2010-12-11

9. Endoglin deficiency impairs VEGFR2 but not FGFR1 or TIE2 activation and alters VEGF-mediated cellular responses in human primary endothelial cells.

Authors: Qiuwang Zhang; Chenxi Wang; Anthony Cannavicci; Marie E Faughnan; Michael J B Kutryk
Journal: Transl Res Date: 2021-04-22 Impact factor: 10.171

Review 10. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.

Authors: Daniela S Ardelean; Michelle Letarte
Journal: Front Genet Date: 2015-02-11 Impact factor: 4.599